ABSTRACT
Giant basal cell carcinoma (BCC) is defined as a tumor with a diameter of 5 cm or more. Surgery, the treatment of choice for any type of BCC, can cause considerable anatomical damage in large tumors. In 2 patients with giant BCC we therefore provided neoadjuvant treatment with a combination of oral acitretin and topical 5% imiquimod. Acitretin is a systemic retinoid used for primary prevention of non-melanoma skin cancer. Imiquimod is an immunomodulator whose approved indications include treatment of non-facial superficial BCC less than 2 cm in diameter. Previous studies have demonstrated a synergic anticancer effect of both drugs in vitro and in vivo. This combination produced a marked reduction in tumor mass in our patients. Later we were able to provide definitive treatment, which achieved complete remission of the tumors.
[Oral acitretin and topical imiquimod as neoadjuvant treatment for giant basal cell carcinoma]
Riferimento:
Actas Dermosifiliogr. 2012 Mar;103(2):149-52.
Autori:
Sanmartín V, Aguayo R, Baradad M, Casanova JM..vsanmartin6@yahoo.es
Fonte:
Actas Dermosifiliogr. 2012 Mar;103(2):149-52.
Anno:
2012
Azione:
L'acitretina è un retinoide sistemico usato per la prevenzione primaria del cancro della pelle non-melanoma. Imiquimod è un immunomodulatore le cui indicazioni approvate includono il trattamento del carcinoma superficiale gigante a cellule basali (BCC).
Target:
Acitretina-imiquimod/carcinoma superficiale gigante a cellule basali
Sostanze: